OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
The profits were bolstered by the Boehringer Ingelheim MEK program income
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Deal signed with AOP Orphan for US commercial rights
A veteran in cell therapy and oncology commercialisation
This work has been published in the journal ‘ACS applied materials and interface’
The goal for the project is the identification and optimization of anti-viral compounds.
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Subscribe To Our Newsletter & Stay Updated
